Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.
View Top Employees from Femasys Inc.Website | http://www.femasys.com |
Ticker | FEMY |
Revenue | $12 million |
Funding | $60.1 million |
Employees | 41 (39 on RocketReach) |
Founded | 2004 |
Address | 3950 Johns Creek Ct Suite 100, Suwanee, Georgia 30024, US |
Phone | (770) 500-3910 |
Fax | (404) 581-5903 |
Technologies |
JavaScript,
HTML,
PHP
+26 more
(view full list)
|
Industry | Manufacturing, Medical Equipment Manufacturing, Medical Devices & Equipment, Biotechnology, Science and Engineering, Health Care, Medical Device, Robotics, Hardware, Software, Women's |
Web Rank | 35 Million |
Competitors | Atc Technologies Inc, Biometrix, Biosensors International Group, Ltd, Broncus Medical, Inc., Tracoe Medical GmbH |
SIC | SIC Code 38 Companies, SIC Code 384 Companies |
NAICS | NAICS Code 339 Companies, NAICS Code 33 Companies |
Looking for a particular Femasys Inc. employee's phone or email?
The Femasys Inc. annual revenue was $12 million in 2024.
Dov Elefant is the CFO of Femasys Inc..
39 people are employed at Femasys Inc..
Femasys Inc. is based in Suwanee, Georgia.
The NAICS codes for Femasys Inc. are [339, 33].
The SIC codes for Femasys Inc. are [38, 384].